🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

3,067 results for “Hospital” Clear

  1. AK104

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Resectable Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  2. AK104, nab-paclitaxel, carboplatin

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  3. AK105 and anlotinib

    The First People's Hospital of Lianyungang

    Cervical Cancer

    phase 2 small molecule active

    1 trial

  4. AK117

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  5. AS01 adjuvant (0.5 mL intramuscular)

    Hospital Authority, Hong Kong

    Immune System Responses and Trained Immunity After AS01 Administration

    phase 2 mab active

    1 trial

  6. ASC22

    The First People's Hospital of Lianyungang

    Chronic Hepatitis b

    phase 2 small molecule completed

    1 trial

  7. ASC30 tablets

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    T2DM (Type 2 Diabetes Mellitus)

    phase 2 small molecule active

    1 trial

  8. ASCT+CD7-CART

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    CD7 Positive

    phase 2 small molecule active

    1 trial

  9. ASLAN001

    Hospital Authority, Hong Kong

    Advanced/ Metastatic Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  10. AUY922

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastrointestinal Stromal Tumor

    phase 2 small molecule active

    1 trial

  11. AZD9291

    Hospital Authority, Hong Kong

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule active

    1 trial

  12. Abatacept s.c.

    The First People's Hospital of Lianyungang

    Abatacept

    phase 2 small molecule active

    1 trial

  13. Abemaciclib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Liver Metastases From Colorectal Cancer (mCRC)

    phase 2 small molecule active

    1 trial

  14. Abiraterone Acetate

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  15. Absorbable and moldable skull base support plate

    The First People's Hospital of Lianyungang

    Sellar Tumor

    phase 2 other active

    1 trial

  16. Acetohydroxamic Acid

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Multidrug-Resistant Tuberculosis

    phase 2 small molecule active

    1 trial

  17. Ad-HGF

    The First People's Hospital of Lianyungang

    Myocardial Infarction

    phase 2 small molecule active

    1 trial

  18. Ad-HGF

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Ischemic Heart Disease

    phase 2 small molecule active

    1 trial

  19. Adebellizumab

    The First People's Hospital of Lianyungang

    Resectable Lung Non-Small Cell Carcinoma

    phase 2 small molecule active

    1 trial

  20. Adebrelimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  21. Adebrelimab (PD-L1 inhibitor)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pancreatic Cancer Metastatic

    phase 2 small molecule active

    1 trial

  22. Adebrelimab combined with irinotecan liposomal (II), oxaliplatin, and 5-FU/LV

    The First People's Hospital of Lianyungang

    Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  23. Adebrelimab+Albumin paclitaxel +Cisplatin

    The First People's Hospital of Lianyungang

    Locally Advanced Hypopharyngeal Cancer

    phase 2 small molecule active

    1 trial

  24. Adebrelimab, paclitaxel, carboplatin, bevacizumab, fluzoparib

    The First People's Hospital of Lianyungang

    Platinum-sensitive Relapsed Ovarian Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources